Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020114616 - TOPICAL TREATMENT OF IMMUNE CHECKPOINT INHIBITOR INDUCED DIARRHOEA, COLITIS OR ENTEROCOLITIS USING ANTIBODIES AND FRAGMENTS THEREOF

Publication Number WO/2020/114616
Publication Date 11.06.2020
International Application No. PCT/EP2018/084057
International Filing Date 07.12.2018
IPC
C07K 16/24 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 9/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
A61K 9/14 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 9/0014
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0014Skin, i.e. galenical aspects of topical compositions
A61K 9/0053
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0053Mouth and digestive tract, i.e. intraoral and peroral administration
A61K 9/145
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
145with organic compounds
C07K 16/241
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
241Tumor Necrosis Factors
Applicants
  • TILLOTTS PHARMA AG [CH]/[CH]
Inventors
  • FURRER, Esther Maria
  • VARUM, Felipe
  • SPLEISS, Johannes
  • NEDELJKOVIC, Marijana
  • GERSTNER, Ortrud
  • BRAVO, Roberto
  • BRUNO, Cristina
Agents
  • KELLER, Günter
  • BEST, Michael
  • TEIPEL, Stephan
  • KALHAMMER, Georg
Priority Data
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) TOPICAL TREATMENT OF IMMUNE CHECKPOINT INHIBITOR INDUCED DIARRHOEA, COLITIS OR ENTEROCOLITIS USING ANTIBODIES AND FRAGMENTS THEREOF
(FR) TRAITEMENT TOPIQUE D'UNE DIARRHÉE, D'UNE COLITE OU D'UNE ENTÉROCOLITE INDUITE PAR UN INHIBITEUR DE POINT DE CONTRÔLE IMMUNITAIRE AU MOYEN D'ANTICORPS ET DE FRAGMENTS DE CEUX-CI
Abstract
(EN)
The present invention relates to the therapeutic topical use of compositions containing antibody molecules or functional fragments or derivatives specific to tumour necrosis factor alpha (TNFα), for treating or preventing immune checkpoint (ICP) inhibitor-induced adverse events.
(FR)
La présente invention concerne l'utilisation topique thérapeutique de compositions contenant des molécules d'anticorps ou des fragments fonctionnels ou des dérivés spécifiques du facteur de nécrose tumorale alpha (TNFα), pour traiter ou prévenir des événements indésirables induits par un inhibiteur de point de contrôle immunitaire (ICP).
Latest bibliographic data on file with the International Bureau